Abstract
Objectives
Obesity is increasing in developed countries and is a risk factor for pancreatic cancer (PaC). We previously reported that obesity was associated with pancreatic cystic lesions (PCLs), which are both precursors of, and risk factors for, PaC. In the present study, we further investigated the relationship between visceral adiposity and adiponectin levels and the extent of PCLs.
Methods
Individuals who underwent comprehensive health screening at our institution between January 2008 and March 2013 were analyzed. PCLs were diagnosed via magnetic resonance imaging using a 3.0 Tesla system. The volumes of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were measured from computed tomographic volume data. Serum levels of adiponectin were measured using a sandwich enzyme-linked immunosorbent assay.
Results
The prevalences of PCLs were 14.2% in males (N = 2683; mean age, 56.4 years) and 16.2% in females (N = 1741; mean age, 57.1 years). The prevalence of PCLs increased gradually as VAT volume increased (P < 0.001). PCLs were more prevalent in individuals with high adiponectin levels (18.7% vs. 13.8%, P = 0.005). VAT volume (odds ratio [OR] for the highest quartiles, 1.52 [1.07–2.16]; P = 0.025) and adiponectin level (OR for the highest quartiles, 1.31 [1.08–1.59]; P = 0.007) but not SAT volume (P = 0.828) was significantly associated with PCLs in multivariate analyses.
Conclusions
Visceral adiposity and high adiponectin levels were associated with PCL prevalence. Further work is needed to explore the relationships between visceral adiposity and adiponectin levels, and PCLs and PaC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nagai M, Ohkubo T, Murakami Y, Takashima N, Kadota A, Miyagawa N, et al. Secular trends of the impact of overweight and obesity on hypertension in Japan, 1980–2010. Hypertens Res. 2015;38:790–5.
Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J. 2014;78:2807–18.
Examination Committee of Criteria for ‘Obesity Disease’ in J, Japan Society for the Study of O. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.
Keum N, Lee DH, Kim R, Greenwood DC, Giovannucci EL. Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies. Ann Oncol. 2015;26:1101–9.
Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, Park MJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol. 2010;105:178–87.
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–51.
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.
Tilg H, Wolf AM. Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets. 2005;9:245–51.
Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913.
Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.
Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88:993–7.
Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–94.
Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11(2 Pt 1):466–72.
Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005;65:1168–72.
Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol. 2008;168:1047–55.
Grote VA, Rohrmann S, Dossus L, Nieters A, Halkjaer J, Tjonneland A, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer. 2012;130:2428–37.
Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013;105:95–103.
Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138:427–3. Discussion 33–4
Goh BK, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK, et al. Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg. 2006;192:148–54.
Kimura W. How many millimeters do atypical epithelia of the pancreas spread intraductally before beginning to infiltrate? Hepatogastroenterology. 2003;50:2218–24.
Chernyak V, Flusberg M, Haramati LB, Rozenblit AM, Bellin E. Incidental pancreatic cystic lesions: is there a relationship with the development of pancreatic adenocarcinoma and all-cause mortality? Radiology. 2015;274:161–9.
Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010;105:2079–84.
de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8:806–11.
Matsubara S, Tada M, Akahane M, Yagioka H, Kogure H, Sasaki T, et al. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Pancreas. 2012;41:1241–6.
Girometti R, Intini S, Brondani G, Como G, Londero F, Bresadola F, et al. Incidental pancreatic cysts on 3D turbo spin echo magnetic resonance cholangiopancreatography: prevalence and relation with clinical and imaging features. Abdom Imaging. 2011;36:196–205.
Mizuno S, Isayama H, Nakai Y, Yoshikawa T, Ishigaki K, Matsubara S, et al. Prevalence of pancreatic cystic lesions is associated with diabetes mellitus and obesity: an analysis of 5296 individuals who underwent a preventive medical examination. Pancreas. 2017;46:801–5.
Nemoto M, Yeernuer T, Masutani Y, Nomura Y, Hanaoka S, Miki S, et al. Development of automatic visceral fat volume calculation software for CT volume data. J Obes. 2014;2014:495084.
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
Fujino M, Miura S, Kiya Y, Tominaga Y, Matsuo Y, Karnik SS, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT(1) receptor-dependent and -independent beneficial effects. Hypertens Res. 2010;33:1044–52.
Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36:1–8.
Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459–64.
Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:843–52.
Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920–31.
Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–8.
Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.
Yamamoto S, Nakagawa T, Matsushita Y, Kusano S, Hayashi T, Irokawa M, et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care. 2010;33:184–9.
Micucci C, Valli D, Matacchione G, Catalano A. Current perspectives between metabolic syndrome and cancer. Oncotarget. 2016;7:38959–72.
Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.
Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–9.
Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20:625–33.
Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007;35:16–21.
Pezzilli R, Barassi A, Corsi MM, Morselli-Labate AM, Campana D, Casadei R, et al. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45:93–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The Department of Computational Radiology and Preventive Medicine is sponsored by HIMEDIC, Inc. and Siemens Japan KK. However, this work is independent of these sponsors. All other declare that they have no conflict of interest.
Additional information
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:http://www.textcheck.com/certificate/GV2NlV
Rights and permissions
About this article
Cite this article
Mizuno, S., Nakai, Y., Isayama, H. et al. Visceral adiposity and high adiponectin levels are associated with the prevalence of pancreatic cystic lesions. Int J Obes 43, 169–175 (2019). https://doi.org/10.1038/s41366-018-0083-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41366-018-0083-4